A

AlloVir
D

ALVR

9.26000
USD
-0.01
(-0.11%)
مفتوح الان
حجم التداول
760
الربح لكل سهم
0
العائد الربحي
-
P/E
-0
حجم السوق
46,676,326
أصول ذات صلة
    AAPL
    AAPL
    0.660
    (0.30%)
    224.440 USD
    AMZN
    AMZN
    -0.520
    (-0.22%)
    234.430 USD
    GOOGL
    GOOGL
    1.730
    (0.87%)
    200.040 USD
    MSFT
    MSFT
    -2.46
    (-0.55%)
    443.70 USD
    NVDA
    NVDA
    -0.990
    (-0.67%)
    146.135 USD
    S
    SNAP
    0.180
    (1.72%)
    10.640 USD
    TSLA
    TSLA
    -1.23
    (-0.30%)
    412.30 USD
    ZM
    ZM
    -0.040
    (-0.05%)
    79.220 USD
    المزيد
الأخبار المقالات

العنوان: AlloVir Inc

القطاع: Healthcare
الصناعة: Biotechnology
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.